Based on a library comprising of 616 FDA‐approved drugs (Table S2, Supporting Information), two CRC cell lines, HCT116 (high level of mTOR) and HT29 (low level of mTOR), were subjected to cell viability analysis (10 μM, 72 h; Figure 1D,E). This evidence concerns the gene MTOR and colorectal carcinoma.